T Telehealth Options

Medication comparison

Zepbound vs Wegovy: which weight-loss medication is better?

Zepbound and Wegovy are FDA-approved chronic weight-management medications for certain patients. Zepbound has shown greater average weight loss in a head-to-head trial, but the better choice depends on your health history, side effects, insurance coverage, and clinician guidance.

Check eligibility factors Compare medications
Home Zepbound vs Wegovy: Weight-Loss Medication Comparison

Zepbound

Tirzepatide for chronic weight management in certain adults.

Learn more

Wegovy

Semaglutide for chronic weight management in certain adults.

Learn more

Eligibility

BMI, health history, contraindications, and clinician review matter.

Learn more

Quick comparison

Feature Zepbound Wegovy
Active ingredient Tirzepatide. Semaglutide.
Drug class GIP and GLP-1 receptor agonist. GLP-1 receptor agonist.
Administration Once-weekly injection with dose escalation. Once-weekly injection with dose escalation.
Average weight loss in SURMOUNT-5 20.2% average body-weight reduction at 72 weeks in adults without diabetes. 13.7% average body-weight reduction at 72 weeks in adults without diabetes.
Common side effects Gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, or abdominal discomfort may occur. Gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, or abdominal discomfort may occur.
Cost and coverage Depends on insurance, cash-pay pricing, manufacturer programs, pharmacy access, and indication. Depends on insurance, cash-pay pricing, manufacturer programs, pharmacy access, and indication.
Decision-maker Licensed clinician after individual review. Licensed clinician after individual review.

Find out which weight-loss treatment may be right for you

Use the eligibility quiz to prepare for a licensed telehealth consultation about Zepbound, Wegovy, or other medical weight-loss options.

  • Complete a quick educational eligibility questionnaire.
  • Prepare to speak with a licensed provider.
  • Discuss treatment options without a prescription guarantee.
Check eligibility

What Zepbound is

Zepbound is the brand name for tirzepatide when used for chronic weight management in certain adults. It acts on both GIP and GLP-1 receptors and is used with a reduced-calorie diet and increased physical activity according to FDA labeling.

What Wegovy is

Wegovy is the brand name for semaglutide when used for chronic weight management in certain adults and some adolescents. It acts on GLP-1 receptors and is also used with reduced-calorie diet and increased physical activity according to its labeling.

Key differences

The main difference is receptor activity: Zepbound activates GIP and GLP-1 receptors, while Wegovy activates GLP-1 receptors. Both are injectable incretin-based medications, both require gradual dose escalation, and both should be used under clinician supervision.

  • Zepbound active ingredient: tirzepatide.
  • Wegovy active ingredient: semaglutide.
  • Both are typically discussed as part of a broader medical weight-loss plan.

Effectiveness comparison

In the SURMOUNT-5 head-to-head trial, adults with obesity or overweight and at least one weight-related condition, but without diabetes, had greater average weight loss with tirzepatide than semaglutide at 72 weeks. That does not mean Zepbound is the best choice for every patient; individual response, risks, coverage, and tolerability still matter.

Side effects comparison

Both medications can cause gastrointestinal side effects, especially during dose escalation. A telehealth provider should explain common symptoms, warning signs, missed-dose guidance, dehydration risk, and when severe abdominal pain, persistent vomiting, allergic reaction symptoms, or other concerning symptoms require urgent care.

Cost and insurance comparison

Cost can decide which medication is realistic. Coverage may vary by employer plan, diagnosis, prior authorization requirements, pharmacy availability, manufacturer savings programs, and whether the medication is prescribed for an FDA-approved use. Ask the provider what costs are included in consultation, membership, labs, and medication fulfillment.

Which medication may be right for you

The right choice should come from a clinician review of BMI, weight-related conditions, medication history, contraindications, pregnancy plans, side-effect tolerance, insurance, and treatment goals. Some patients may be better candidates for Zepbound, Wegovy, another medication, or a non-medication plan.

Telehealth questions to ask

Use a telehealth consultation to clarify which product fits your situation and how the provider handles side effects, interruptions, or changes in coverage.

  • Which medication is clinically appropriate for me and why?
  • What side effects should I expect, and which symptoms are urgent?
  • What happens if supply or insurance coverage changes?

Related telehealth guides

Best online weight-loss clinic comparison

Read guide

Frequently asked questions

Is Zepbound stronger than Wegovy?

In the SURMOUNT-5 head-to-head trial, tirzepatide led to greater average weight loss than semaglutide. “Stronger” is not the only decision factor, because side effects, health history, coverage, and clinician judgment still matter.

Which medication leads to more weight loss?

In SURMOUNT-5, participants using tirzepatide had greater average weight loss than participants using semaglutide at 72 weeks. Individual results vary.

Can I get Zepbound or Wegovy through telehealth?

A licensed telehealth clinician may prescribe when state rules allow and the medication is clinically appropriate after evaluation.

What are the side effects of Zepbound and Wegovy?

Both can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Serious symptoms should be discussed with a clinician or evaluated urgently when appropriate.

Are Zepbound and Wegovy used with lifestyle changes?

Yes. Their weight-management labeling describes use with reduced-calorie diet and increased physical activity.

Sources reviewed

Summary

Zepbound contains tirzepatide, a GIP and GLP-1 receptor agonist. Wegovy contains semaglutide, a GLP-1 receptor agonist. In SURMOUNT-5, tirzepatide led to greater average weight loss than semaglutide, but treatment choice should be individualized by a licensed clinician.

Medical disclaimer

This content is for education only and is not medical advice. Medication decisions should be made with a licensed clinician who can review your full health history. Seek urgent care for emergency symptoms.